Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money.
Today we look at two noteworthy recent insider buys.
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money.
Today we look at two noteworthy recent insider buys.
On Thursday, RAPT Therapeutics', William JL Rieflin, made a $162,200 purchase of RAPT, buying 10,000 shares at a cost of $16.22 each.
Rieflin was up about 15.6% on the purchase at the high point of today's trading session, with RAPT trading as high as $18.75 in trading on Monday.
RAPT Therapeutics is trading up about 6.1% on the day Monday.
This buy marks the first one filed by Rieflin in the past year.
And also on Thursday, Director Cam L.
Garner purchased $161,042 worth of Zogenix, purchasing 8,000 shares at a cost of $20.13 a piece.
Before this latest buy, Garner made one other buy in the past twelve months, purchasing $174,647 shares for a cost of $21.83 a piece.
Zogenix is trading up about 4.8% on the day Monday.
So far Garner is in the green, up about 3.9% on their purchase based on today's trading high of $20.91.